Streptozotocin-induced diabetic cynomolgus monkeys serve as a viable animal model for studying hypertriglyceridemia with low HDL cholesterol and its role in atherosclerosis.
Answers are grounded in this paper and cite their sources.
Supports STZ-diabetic cynomolgus monkeys as model for diabetic dyslipidemia; leaves open human translation to atherosclerosis.
Hypertriglyceridemia with low high-density lipoprotein (HDL) cholesterol is a risk factor of cardiovascular disease. We attempted to create an animal model of hypertriglyceridemia with low HDL cholesterol by intravenously injecting 30 mg/kg body weight streptozotocin (STZ) to cynomolgus monkeys. This induced hypoinsulinemia and resulted in a decrease in postheparin plasma lipoprotein lipase (LPL) activity and LPL enzyme mass, reduction of plasma HDL cholesterol and elevation of triglycerides. Low HDL cholesterol subsequently caused a reduction of HDL2b cholesterol, while hypertriglyceridemia caused an elevation of very low-density lipoprotein (VLDL) triglyceridemia. Apolipoprotein CII, a co-factor of LPL, was not affected by STZ administration. These results show that hypertriglyceridemia with low HDL cholesterol results from a reduction of LPL activity without affecting apolipoprotein CII after STZ administration. The STZ-induced diabetic cynomolgus monkey is a model of hypertriglyceridemia with low HDL cholesterol, and may be potentially beneficial for studying atherosclerosis caused by hypertriglyceridemia with low HDL cholesterol.
No takes yet. Share an insight, caveat, or question.
Tsutsumi et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: